文献速递肿瘤 PET/CT核素与放射性配体治疗

系列[⁶⁸Ga]Ga-FAPI-04 PET/CT在预测乳腺癌新辅助化疗病理反应和评估疗效中的价值

The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-07-12

该回顾性研究纳入64例经活检证实的乳腺癌患者,在新辅助化疗前、2周期后及术前进行系列[⁶⁸Ga]Ga-FAPI-04 PET/CT检查,比较病理完全缓解(pCR)组与非pCR组参数变化。结果显示pCR组参数下降显著大于非pCR组,ΔSUVmean1-2、ΔFTV1-2、ΔSUVmean1-3和ΔFTV1-3为pCR的独立预测因素,ΔFTV1-3的AUC为0.906。作者认为系列[⁶⁸Ga]Ga-FAPI-04 PET/CT有助于早期预测病理反应和评估疗效。

要点

  • pCR组[⁶⁸Ga]Ga-FAPI-04 PET/CT参数下降显著大于非pCR组(均P<0.001)。
  • ΔSUVmean1-2、ΔFTV1-2、ΔSUVmean1-3和ΔFTV1-3为pCR独立预测因素。
  • ΔFTV1-3预测pCR的AUC为0.906,与ΔFTV1-2的0.869差异未达统计学显著。

核心结论

  • 系列[⁶⁸Ga]Ga-FAPI-04 PET/CT有助于早期预测乳腺癌新辅助化疗的病理反应并评估疗效,但需更大样本的前瞻性研究。

研究设计与样本

  • 回顾性纳入64例经活检证实的乳腺癌患者,在新辅助化疗前(基线,PET1)、2周期后( interim,PET2)和术前(PET3)进行系列[⁶⁸Ga]Ga-FAPI-04 PET/CT检查。

主要发现

  • 所有患者[⁶⁸Ga]Ga-FAPI-04 PET/CT参数(ΔSUVmax、ΔSUVmean、ΔFTV、ΔTLF)均显著下降,pCR组下降幅度显著大于非pCR组(均P<0.001)。
  • 在非pCR组中,原发乳腺病灶和转移淋巴结的总FTV变化(ΔtFTV1-2和ΔtFTV1-3)与残留肿瘤负荷(RCB)评分呈中度相关。
  • 多因素logistic回归显示ΔSUVmean1-2(P=0.027)、ΔFTV1-2(P=0.006)、ΔSUVmean1-3(P=0.032)和ΔFTV1-3(P=0.010)是预测pCR的独立因素。
  • ROC曲线分析显示ΔSUVmean1-3(AUC=0.848)和ΔFTV1-3(AUC=0.906)的预测性能分别略高于ΔSUVmean1-2(AUC=0.825)和ΔFTV1-2(AUC=0.869),但差异无统计学意义(P>0.05)。

临床怎么用

  • 作者认为系列[⁶⁸Ga]Ga-FAPI-04 PET/CT有助于早期预测乳腺癌新辅助化疗的病理反应并评估疗效。
  • 作者指出需更大样本的前瞻性研究进一步验证。

局限性

  • 原文指出需更大样本的前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinical utility of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT for predicting pathological response and evaluating therapeutic efficacy in breast cancer (BC) patients receiving neoadjuvant chemotherapy (NAC). METHODS: A total of 64 biopsy-confirmed patients with BC were retrospectively included. Serial [68Ga]Ga-FAPI-04 PET/CT scans were conducted at three time points: prior to NAC (baseline, PET1), after two cycles of NAC (interim, PET2), and before surgery (pre-surgery, PET3). PET/CT parameters derived from the primary BC lesions were recorded before and after NAC. The changes in these parameters were compared between the pathological complete response (pCR) and the non-pCR group. Logistic regression was used to assess the predictive value of [68Ga]Ga-FAPI-04 PET/CT parameters for predicting pCR. Receiver operating characteristic (ROC) curve analysis was employed to determine the optimal cutoff values for predicting pCR. DeLong's test was applied to statistically assess differences in the area under the ROC curves (AUC). RESULTS: Significant reductions in [68Ga]Ga-FAPI-04 PET/CT parameters (ΔSUVmax, ΔSUVmean, ΔFTV, ΔTLF) were observed among all patients, with significantly greater decreases in the pCR group compared to the non-pCR group (all P < 0.001). In the non-pCR group, the total FTV (ΔtFTV1-2 and ΔtFTV1-3) of primary breast lesions and metastatic lymph nodes showed moderate correlation with the residual cancer burden (RCB) score. Multivariate logistic regression identified ΔSUVmean1-2 (P = 0.027), ΔFTV1-2 (P = 0.006), ΔSUVmean1-3 (P = 0.032), and ΔFTV1-3 (P = 0.010) as independent predictors for predicting pCR. On the basis of the ROC curve analysis, ΔSUVmean1-3 (AUC = 0.848) and ΔFTV1-3 (AUC = 0.906) showed slightly higher predictive performance than ΔSUVmean1-2 (AUC = 0.825) and ΔFTV1-2 (AUC = 0.869), respectively, but the difference was not statistically significant (P > 0.05). CONCLUSION: This study demonstrates that serial [68Ga]Ga-FAPI-04 PET/CT facilitates early prediction of pathological response to neoadjuvant chemotherapy in breast cancer, as well as assessment of therapeutic efficacy. Prospective studies with larger samples are needed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zheng S, Xu F, Chen Y, et al. The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40650678. doi:10.1007/s00259-025-07444-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。